戴维医疗
(300314)
| 流通市值：16.59亿 | | | 总市值：33.24亿 |
| 流通股本：1.44亿 | | | 总股本：2.88亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 112,797,919.57 | 584,030,132.77 | 392,655,821.72 | 251,256,793.39 |
| 营业收入 | 112,797,919.57 | 584,030,132.77 | 392,655,821.72 | 251,256,793.39 |
| 二、营业总成本 | 106,008,569.07 | 506,371,105.43 | 330,449,667.87 | 206,184,417.31 |
| 营业成本 | 56,493,086.26 | 270,868,395.16 | 171,097,521.78 | 104,529,425.88 |
| 税金及附加 | 1,115,729.45 | 7,108,903.38 | 3,996,494.28 | 2,972,492.27 |
| 销售费用 | 18,403,805.43 | 100,993,412.96 | 70,219,784.52 | 45,224,299.76 |
| 管理费用 | 14,965,923.94 | 73,820,201.42 | 49,909,919.46 | 32,803,000.86 |
| 研发费用 | 10,534,738.58 | 59,304,913.48 | 40,776,180.11 | 25,524,506.58 |
| 财务费用 | 4,495,285.41 | -5,724,720.97 | -5,550,232.28 | -4,869,308.04 |
| 其中:利息费用 | 65,554.34 | 428,890.08 | 307,435.87 | 226,363.22 |
| 其中:利息收入 | 3,358,935.44 | 12,309,333.11 | 7,946,649.81 | 4,856,215.64 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,426,183.95 | 1,777,206.29 | - | - |
| 加:投资收益 | 1,230,564.44 | 13,529,780.77 | 12,924,163.21 | 7,928,854.87 |
| 资产处置收益 | - | -389,071.48 | -389,071.48 | -104,015.1 |
| 资产减值损失(新) | - | -2,140,826.65 | - | - |
| 信用减值损失(新) | -298,756.63 | -1,323,457.98 | -1,255,367.79 | -867,144.55 |
| 其他收益 | 2,435,517.67 | 9,535,432.81 | 9,284,788.67 | 6,457,659.71 |
| 四、营业利润 | 11,582,859.93 | 98,648,091.1 | 82,770,666.46 | 58,487,731.01 |
| 加:营业外收入 | 18,102.78 | 345,739.72 | 60,018.56 | 48,687.02 |
| 减:营业外支出 | 275,165.45 | 336,349.97 | 637,006.49 | 506,782.44 |
| 五、利润总额 | 11,325,797.26 | 98,657,480.85 | 82,193,678.53 | 58,029,635.59 |
| 减:所得税费用 | 1,439,978.75 | 11,604,161.16 | 9,575,835.76 | 7,052,941.3 |
| 六、净利润 | 9,885,818.51 | 87,053,319.69 | 72,617,842.77 | 50,976,694.29 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 9,885,818.51 | 87,053,319.69 | 72,617,842.77 | 50,976,694.29 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 9,885,818.51 | 87,053,319.69 | 72,617,842.77 | 50,976,694.29 |
| 扣除非经常损益后的净利润 | 6,173,470.82 | 67,024,300.72 | 56,076,408.39 | 40,710,888.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.3 | 0.25 | 0.18 |
| (二)稀释每股收益 | 0.03 | 0.3 | 0.25 | 0.18 |
| 八、其他综合收益 | -407,408.33 | 2,662,473.46 | 2,715,646.99 | 3,245,598.9 |
| 归属于母公司股东的其他综合收益 | -407,408.33 | 2,662,473.46 | 2,715,646.99 | 3,245,598.9 |
| 九、综合收益总额 | 9,478,410.18 | 89,715,793.15 | 75,333,489.76 | 54,222,293.19 |
| 归属于母公司股东的综合收益总额 | 9,478,410.18 | 89,715,793.15 | 75,333,489.76 | 54,222,293.19 |
| 公告日期 | 2026-04-23 | 2026-04-03 | 2025-10-23 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |